Navigation Links
Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
Date:9/12/2007

CRANBURY, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) stated today that the press release issued on September 11, 2007 by Competitive Technologies, Inc. (Amex: CTT) relating to a material breach and termination of a license agreement was false and misleading.

The press release issued by CTT stated that "Competitive Technologies Terminates License Agreement with Palatin Technologies." However, the Notice of Termination sent by CTT to Palatin the day before expressly stated Palatin had "sixty (60) days from the date of this letter to cure" the alleged defaults. The statement made by CTT that the underlying license agreement between Palatin and CTT had been terminated is false and misleading.

The underlying Palatin/CTT license agreement relates to patent rights for compounds and methods used for treatment of sexual dysfunction, including a compound called melanotan-II (MT-II) or PT-14. Palatin ceased development of PT-14 in 2000 and has no plans for further development of the compound. Palatin's bremelanotide compound was independently developed and patented by Palatin, and Palatin believes that bremelanotide is not covered by any of CTT's patents or patent rights. Whether bremelanotide is subject to the license agreement is an issue in an ongoing arbitration proceeding initiated by CTT in June 2006.

Palatin received a Notice of Termination on this matter from CTT in the late afternoon of September 10, 2007. The Notice of Termination alleges that Palatin has breached the Palatin/CTT agreement as a result of an amendment in December 2005 to the Collaborative Development and Marketing Agreement between Palatin and King Pharmaceuticals, Inc. (NYSE: KG). Palatin disputes that the amendment breaches the Palatin/CTT agreement in any way. Nevertheless, during the morning of September 10, 2007, Palatin announced via a press release and conference call that the King agreement had been terminated. Therefore, any alleged breach to the Palatin/CTT license agreement was eliminated by the termination of the King agreement, which was announced prior to CTT sending Notice of Termination.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities of ... diverse pathologies ranging from food poisoning and catheter infections to gum disease and the ... tens of billions of dollars per year, there is currently a paucity of means ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... re-engineer their control technology again and again. METTLER TOLEDO has released two new ... The videos illustrate how integration of the ACT350 into Siemens and Allen Bradley ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, ... Maryland Biohealth community in developing and issuing recommendations to grow Maryland's biohealth industry ... Hub by 2023. , The recommendations are contained in a ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ work is ... of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday ... to excellence in clinical laboratory services and regulations. , “We are pleased ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):